NLRP3 and diabetic cardiomyopathy: Moreover, the inhibition of NLRP3 inflammasome activation can alleviate diabetic complications, including diabetic cardiomyopathy, diabetic nephropathy, diabetic retinopathy, diabetes-related wound-healing defects, and diabetic vascular endothelial dysfunction [40–44].